Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Acquires 2,000 Shares

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel purchased 2,000 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was bought at an average cost of $11.97 per share, for a total transaction of $23,940.00. Following the completion of the purchase, the chief executive officer now directly owns 5,543,702 shares in the company, valued at approximately $66,358,112.94. This trade represents a 0.04 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.

Snehal Patel also recently made the following trade(s):

• On Monday, December 30th, Snehal Patel bought 3,200 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $11.12 per share, for a total transaction of $35,584.00.

Greenwich LifeSciences Stock Up 1.8 %

Shares of GLSI opened at $13.11 on Tuesday. The stock has a market capitalization of $172.33 million, a P/E ratio of -16.39 and a beta of 1.66. Greenwich LifeSciences, Inc. has a twelve month low of $8.00 and a twelve month high of $21.44. The firm has a fifty day simple moving average of $13.18 and a two-hundred day simple moving average of $14.15.

Hedge Funds Weigh In On Greenwich LifeSciences

Several hedge funds and other institutional investors have recently modified their holdings of GLSI. State Street Corp increased its holdings in Greenwich LifeSciences by 4.4% during the 3rd quarter. State Street Corp now owns 71,408 shares of the company’s stock valued at $1,026,000 after purchasing an additional 3,005 shares during the period. Geode Capital Management LLC grew its position in shares of Greenwich LifeSciences by 4.6% in the 3rd quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock worth $1,919,000 after buying an additional 5,861 shares during the last quarter. Barclays PLC increased its stake in shares of Greenwich LifeSciences by 323.3% during the third quarter. Barclays PLC now owns 8,560 shares of the company’s stock valued at $123,000 after buying an additional 6,538 shares during the period. Rhumbline Advisers bought a new position in shares of Greenwich LifeSciences during the second quarter valued at approximately $117,000. Finally, Bank of New York Mellon Corp purchased a new stake in Greenwich LifeSciences in the second quarter worth $264,000. 4.16% of the stock is owned by institutional investors.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.